Clinical Research For Baishile Capsule In The Treatment Of Depression In Liver-qi Stagnation Syndrome

Objective:To observe the clinical safety and effectiveness of Baishile Capsule on the Depression in Liver-qi Stagnation Syndrome.Methods:60 patients of Depression in Liver-qi Stagnation Syndrome were selected, following the principles of evidence-based medicine and DME, randomly divided into Traditional Chinese medicine group and Western medicine group, were correspondly given Baishile Capsule and Fluoxetine, during the treatment of 3 weeks, observed the patients' Self-Rating Depression Scale, Hamilton Depression Rating Scale and Symptom before and after treatment to evaluate their curative effect.Results:1.There were significant differences (P<0.05)of comparision of the Clinical curative effect of two groups between pre-treatment and post-treatment. After treatment, there was no significant difference between Chinese medicine group and Western medicine group (P>0.05).2.There were significant differences(P<0.05)of comparision of syndrome of Depression of two groups between pre-treatment and post-treatment. After treatment, there were significant differences (P<0.05)of comparision of syndrome of Depression between Western medicine group and Chinese medicine group.3.There were significant differences(P<0.05)of comparision of HAMD of two groups between pre-treatment and post-treatment. After treatment, there were significant differences (P<0.05)of comparision of HAMD between Western medicine group and Chinese medicine group.Conclusion:There was no significant difference on the clinical effect of Depression in Liver-qi Stagnation Syndrome between Baishile Capsule and Fluoxetine. However, in improved the syndrome of Depression, Baishile Capsule was better.